Panacea Biotec Limited (NSE:PANACEABIO)
India · Delayed Price · Currency is INR 411.10
-2.55 (-0.62%)
Aug 21, 2026, 3:29 PM IST
Panacea Biotec Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 6,726 | 6,398 | 5,591 | 5,592 | 4,599 | 6,612 | |
Revenue Growth | 10.26% | 14.43% | -0.01% | 21.57% | -30.44% | 5.83% |
Cost of Revenue | 3,050 | 2,805 | 1,995 | 2,301 | 2,527 | 2,622 |
Gross Profit | 3,677 | 3,593 | 3,596 | 3,290 | 2,073 | 3,990 |
Selling, General & Admin | 1,792 | 1,808 | 1,973 | 1,643 | 1,517 | 2,050 |
Other Operating Expenses | 1,863 | 1,832 | 1,804 | 1,695 | 1,192 | 1,987 |
Operating Expenses | 3,981 | 3,970 | 4,125 | 3,705 | 3,100 | 4,474 |
Operating Income | -303.8 | -377.2 | -529.78 | -414.69 | -1,027 | -484.18 |
Interest Expense | -63.7 | -60.5 | -29.22 | -26.73 | -38.03 | -1,798 |
Interest & Investment Income | - | - | 77.12 | 84.07 | 120.62 | 33.94 |
Currency Exchange Gain (Loss) | - | - | 36.99 | 36.23 | 20.77 | 5.8 |
Other Non Operating Income (Expenses) | 154.7 | 169 | -9.54 | -9.08 | -6.34 | -10.02 |
EBT Excluding Unusual Items | -212.8 | -268.7 | -454.43 | -330.2 | -930.37 | -2,253 |
Gain (Loss) on Sale of Investments | - | - | 24.5 | 33.41 | 14.47 | 0.01 |
Gain (Loss) on Sale of Assets | - | - | 4.46 | -2.64 | 52.93 | 0.07 |
Asset Writedown | - | - | -13.95 | -46.14 | -29.94 | -15.75 |
Other Unusual Items | 109.2 | 195 | 359.94 | 360.34 | 1,021 | 16,762 |
Pretax Income | -103.6 | -73.7 | -79.48 | 14.77 | 128.05 | 14,494 |
Income Tax Expense | -14.4 | -2.1 | 7.71 | 29.82 | 465.5 | 3,710 |
Earnings From Continuing Operations | -89.2 | -71.6 | -87.19 | -15.05 | -337.45 | 10,783 |
Net Income to Company | -89.2 | -71.6 | -87.19 | -15.05 | -337.45 | 10,783 |
Minority Interest in Earnings | 18 | 17.9 | 3.49 | 3.32 | 5.08 | -0.19 |
Net Income | -71.2 | -53.7 | -83.7 | -11.73 | -332.37 | 10,783 |
Net Income to Common | -71.2 | -53.7 | -83.7 | -11.73 | -332.37 | 10,783 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 61 | 61 | 61 | 61 | 61 | 61 |
Shares Outstanding (Diluted) | 61 | 61 | 61 | 61 | 61 | 61 |
Shares Change | -0.61% | -0.37% | - | - | - | - |
EPS (Basic) | -1.17 | -0.88 | -1.37 | -0.19 | -5.43 | 176.05 |
EPS (Diluted) | -1.17 | -0.88 | -1.37 | -0.19 | -5.43 | 176.05 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -374.1 | -776.74 | -794.08 | -4,634 | -1,210 |
Free Cash Flow Per Share | - | -6.13 | -12.68 | -12.96 | -75.66 | -19.75 |
Gross Margin | 54.66% | 56.16% | 64.31% | 58.85% | 45.07% | 60.35% |
Operating Margin | -4.52% | -5.90% | -9.48% | -7.42% | -22.34% | -7.32% |
Profit Margin | -1.06% | -0.84% | -1.50% | -0.21% | -7.23% | 163.08% |
Free Cash Flow Margin | - | -5.85% | -13.89% | -14.20% | -100.75% | -18.29% |
EBITDA | 28.92 | -46.6 | -207.64 | -72.82 | -641.24 | -56.28 |
EBITDA Margin | 0.43% | -0.73% | -3.71% | -1.30% | -13.94% | -0.85% |
D&A For EBITDA | 332.72 | 330.6 | 322.14 | 341.87 | 386.15 | 427.9 |
EBIT | -303.8 | -377.2 | -529.78 | -414.69 | -1,027 | -484.18 |
EBIT Margin | -4.52% | -5.90% | -9.48% | -7.42% | -22.34% | -7.32% |
Effective Tax Rate | - | - | - | 201.90% | 363.53% | 25.60% |
Revenue as Reported | 6,881 | 6,567 | 5,798 | 5,850 | 5,116 | 6,722 |
Advertising Expenses | - | - | 194.73 | 113.04 | 218.21 | 220.05 |